An expert discusses how a 55-year-old African American man’s case highlights challenges in diagnosing atopic dermatitis in skin of color, emphasizing the importance of recognizing different disease presentations and addressing postinflammatory hyperpigmentation concerns.

An expert discusses how treating older patients with psoriasis, such as a 72-year-old retired teacher, requires addressing cognitive decline, dexterity issues, and comorbidities by considering in-office biologic administration and buy-and-bill processes for Medicare accessibility.

Panelists discuss how treating scalp psoriasis remains challenging due to poor compatibility of traditional topicals with hair and scalp characteristics, emphasizing the need for cosmetically acceptable, well-tolerated formulations that improve adherence and reduce premature escalation to systemic therapy.

An expert discusses how a 5-year-old child with severe atopic dermatitis affecting sleep and school performance demonstrates the need for systemic therapy escalation, with dupilumab being an ideal choice given its efficacy for both atopic dermatitis and comorbid asthma.

Renata Block, DMSc, MMS, PA-C, interviews Andrew Baker, PA-C, MBA, to discuss his role as a sub-investigator in Castle Biosciences’ UTILISE study for cSCC.

An expert discusses how to approach a 58-year-old African American woman with severe prurigo nodularis experiencing extreme itch (9/10 rating) and extensive lesions, emphasizing the need for rapid systemic intervention with nemolizumab due to its faster onset of itch relief compared with other biologics.

Panelists discuss how topical therapies remain essential in psoriasis management across all severities, highlighting the need for simplified, steroid-sparing treatment options that are safe, effective, and easy to use—especially to improve adherence and address patient concerns about adverse effects and complexity.

An expert discusses how managing psoriasis requires personalizing treatment based on patient adherence challenges, access issues, comorbidities such as depression, and practical considerations such as injection comfort and frequency.

An expert discusses how prurigo nodularis represents one of the most severe itching conditions in dermatology, significantly impacting patients' quality of life and sleep, and explains the importance of breaking the itch-scratch cycle while highlighting recent treatment advances with targeted biologics like dupilumab and nemolizumab.

Eileen Cheever, MPAS, PA-C, highlights the growing role of JAK inhibitors in dermatology, including emerging data on prurigo nodularis and adolescent alopecia areata.

Maria Hordinsky, MD, urges dermatology clinicians to consider allergic contact dermatitis when scarring alopecia treatments fail.

Amy Spizuoco, DO, FAOCD, shared how trichoscopy enhances alopecia evaluation by improving diagnostic speed, accuracy, and reducing biopsy need.

Ongoing maintenance therapy is essential to avoid relapse and preserve gains in repigmentation for patients with vitiligo, according to Gina Mangin, MPAS, PA-C.

Orit Markowitz, MD, shares how a color-focused strategy helps spot early malignancies—even 2-mm lesions—across all skin tones.

Adam Friedman, MD, FAAD, outlines a stepwise approach to treating chronic hand eczema, from vehicle selection to systemic therapies and future innovations.

Orit Markowitz, MD, shares how her color wheel method boosts diagnostic clarity in dermoscopy by simplifying how clinicians assess benign lesions.

Adam Friedman, MD, FAAD, breaks down how to differentiate chronic hand eczema from similar conditions using history, morphology, and key clinical clues.

Janelle Ball of BC Educators offers actionable tips to boost prior authorization success and improve patient support in dermatology practices.

Eileen Cheever, MPAS, PA-C, previews the SDPA Summer Dermatology Conference, calling it a can't-miss opportunity to learn, network, and reconnect.

An expert discusses how personalizing systemic atopic dermatitis treatment requires considering factors such as disease severity, patient impact, treatment failures, age, comorbidities, and patient preferences when selecting between biologics and JAK inhibitors.